Carnitine deficiency, organic acidemias, and Reye's syndrome.
about
Carnitine deficiency in inherited organic acid disorders and Reye syndromeAcetyl L-carnitine protects motor neurons and Rohon-Beard sensory neurons against ketamine-induced neurotoxicity in zebrafish embryos.L-Carnitine rescues ketamine-induced attenuated heart rate and MAPK (ERK) activity in zebrafish embryos.Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.Metabolism of valproate to hepatotoxic intermediates.Opposing effects of ketamine and acetyl L-carnitine on the serotonergic system of zebrafish.Organic acidurias: a review. Part 2.Carnitine, valproate, and toxicity.Equine atypical myopathy in the UK: Epidemiological characteristics of cases reported from 2011 to 2015 and factors associated with survival.Valproate-associated hepatotoxicity and its biochemical mechanisms.The biochemical basis of mitochondrial diseases.Reye's syndrome: current concepts.Reye's and Reye-like syndromes, drug-related diseases? (causative agents, etiology, pathogenesis, and therapeutic approaches).Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues.The importance of recognizing secondary carnitine deficiency in organic acidaemias: case report in glutaric acidaemia type II.Carnitine in muscle, serum, and urine of nonprofessional athletes: effects of physical exercise, training, and L-carnitine administration.Supplementation with carnitine reduces the severity of constipation: a retrospective study of patients with severe motor and intellectual disabilities.Preliminary study comparing the effects of locally and systemically applied L-carnitine on the healing of full-thickness skin defects.Inhibition of oxidative metabolism by propionic acid and its reversal by carnitine in isolated rat hepatocytes.Hepatotoxicity in rat following administration of valproic acid.Medium-chain acyl-CoA dehydrogenase deficiency: metabolic effects and therapeutic efficacy of long-term L-carnitine supplementation.A case of carbamylphosphate synthetase-I deficiency associated with secondary carnitine deficiency--L-carnitine treatment of CPS-I deficiency.Clinical variability of isovaleric acidemia in a genetically homogeneous population.L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats.Atypical presentation of VLCAD deficiency associated with a novel ACADVL splicing mutation.Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.Brain mitochondrial citrate synthase and glutamate dehydrogenase: differential inhibition by fatty acyl coenzyme A derivatives.Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.Carnitine, carnitine acetyltransferase, and glutathione in Alzheimer brain.Kinetics of carnitine concentration after switching from oral administration to intravenous injection in hemodialysis patients.l-Carnitine Supplementation in Childhood Epilepsy: Current Perspectives
P2860
Q28332797-7AF0565D-D40D-4A68-BC21-F9D764686756Q33787815-90E78D0F-3B99-4243-841E-9395AFEEA800Q33796903-D9BB5A96-7C63-4511-8DC1-744AD2D0277CQ35690882-5A1E9373-B61A-4EC6-8865-6C1CFA3957D1Q35690886-9A1EB094-E5C9-4A13-ACA9-1FAC038A4810Q37114029-A6977777-8FB0-422D-BD57-3518701E9F0AQ37463522-92617347-4C47-481A-99D3-59397ABB1CB7Q37659363-D5867B67-F89D-4A98-9072-1F007E0ABF8DQ38818815-A41EF19C-4FF1-4BD6-BF43-F5450E78F430Q39602947-3E5A455D-4001-483B-82EE-B581A6E89233Q39642608-2616C3D5-8B26-48C5-8A38-46542EF24BB4Q39754671-706BD301-77ED-45D9-996C-32BF7BD4D64DQ40923041-5C6FA2BF-BBEA-480E-ABC9-ADC866A5BA91Q41159241-9D7D270A-E97D-4876-97F7-849EEC1B65A4Q41771848-33E873F4-7C51-486F-8BD3-C09F1E917D5AQ42027692-B7A08253-BB27-40F3-BDB3-7F14C7D42438Q42293489-5E473BCB-5EBE-48E2-A5D4-CC64FF393D31Q42838524-8B88B054-EDB5-43E1-854B-C49AB5BA19DBQ42853577-B209AEA0-E722-4FA8-9D85-960CFA7683ABQ43648688-838C7820-EAB5-4306-A41E-0FE904D4BDA4Q43697393-B92D34C1-0F87-4BD4-9660-68A017290CB4Q43708921-30ADC100-9648-4759-B7D9-68C92D33715DQ44203821-8F0FDD0B-9DEC-4721-9279-D6BD73E6F986Q44540675-B3DF5551-6710-4848-B47A-9A75AE90E6D6Q46126063-4EC14FFA-7B0D-4F8F-9E31-CE21A466FA6DQ46808934-80E54ACD-DDFD-4D2E-94DD-BCB7B3F6459BQ48111277-1C3A9B71-7CF9-4112-A2EB-85F38303BE5EQ48399220-99B1C4D2-EC63-48DA-9158-AC178B02B997Q53311167-FFFFFD43-2350-40E3-A7DD-260B4593E5A2Q55429109-9EB4257A-601E-4A2F-866C-2EE7ED106976Q56504222-D5103A02-BA7D-4D9F-A478-2262396C82DF
P2860
Carnitine deficiency, organic acidemias, and Reye's syndrome.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@en
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@nl
type
label
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@en
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@nl
prefLabel
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@en
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@nl
P356
P1433
P1476
Carnitine deficiency, organic acidemias, and Reye's syndrome.
@en
P2093
Parker WD Jr
P304
P356
10.1212/WNL.35.7.1041
P407
P577
1985-07-01T00:00:00Z